To all,
After watching the stock price of ACMI get bashed for no justifiable
reason, perhaps it is time to reflect upon the situation if for no
other reason than to maintain ones sanity. Lets consider similar
companies in the field and after comparisons draw some conclusions for
AccuMed.
CYTYC Corp (CYTC)
Sales for trailing twelve months $1.8M
Market Cap $446,891,813
Price/Sales Ratio $22.27
EPS -1.46
(Market Cap)/Sales Ratio $24.42
Zacks' Wall Street Buy Recommendation 1.3
Neopath Inc (NPTH)
Sales for trailing twelve months $9.14M
Market Cap $208,495,500
Price/Sales Ratio $24.54
EPS -1.69
(Market Cap)/Sales Ratio $22.81
Zacks' Wall Street Buy Recommendation 3.0
Neuromedical Systems Inc (NSIX)
Sales for trailing twelve months $8.14M
Market Cap $100,769,500
Price/Sales Ratio $13.81
EPS -1.25
(Market Cap)/Sales Ratio $12.32
Zacks' Wall Street Buy Recommendation Not Rated
Matritech Inc (NMPS)
Sales for trailing twelve months $1.7M
Market Cap $90,392,250
Price/Sales Ratio $48.97
EPS -0.39
(Market Cap)/Sales Ratio $53.17
Zacks' Wall Street Buy Recommendation 1.6
Chromovision Med Sys Inc (CVSN)
Sales for trailing twelve months NONE
Market Cap $160,753,125
Price/Sales Ratio NA
EPS NA
(Market Cap)/Sales Ratio NA
Zacks' Wall Street Buy Recommendation Not Rated
AccuMed International Inc (ACMI)
Sales for trailing twelve months $13.2
Market Cap $33,223,125
Price/Sales Ratio $2.65
EPS -0.68
(Market Cap)/Sales Ratio $2.52
Zacks' Wall Street Buy Recommendation 1.0
Group Average
Sales for trailing twelve months $8.42
Market Cap $173,420,885
Price/Sales Ratio $22.45
EPS -1.09
(Market Cap)/Sales Ratio $20.60
Zacks' Wall Street Buy Recommendation 1.7
What would be ACMI's share price if the company was valued at the
group average for the following:
Based Upon Share Price
Price/Sales Ratio $13.08
(Market Cap)/Sales Ratio $12.01
But is AccuMed average? Consider the following:
1. Only AccuMed has a 1.0 buy recommendation.
2. AccuMed is one of only two in the group projecting to become
profitable next year.
3. Only AccuMed has now been shown to produce an immediate cost
benefit for the laboratories while increasing quality.
4. AccuMed has stated that the sales revenues growth for 1997
came primarily from "increased sales in the microbiology product
line and the addition of the ESP product line." During the
conference call the company now says interest in the cytopathology
side of the company is taking off both nationally and
internationally with systems being sold and contracts being
signed.
5. Projections for Sales Revenues for 1997 is projected in the
$20M range. At this rate of growth AccuMed's current Market Cap
is probably less than what their 1998 Sales Revenues will be!
No other company in this group can come close to saying that.
6. For icing on the cake, AccuMed has just announced that it has
completed corporate consolidation which should reduce operating
expenses next year by $2M.
Can anyone explain to me why the stock is selling so low?
Cisco |
